| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8653109 | The Annals of Thoracic Surgery | 2017 | 8 Pages |
Abstract
Liver cirrhosis per se is not considered as a contraindication for cardiac operations. In the present study, we did not observe a higher 30-day mortality rate in liver cirrhotic patients undergoing TAVR, suggesting TAVR as a feasible alternative with acceptable outcomes in patients with chronic liver disease. Moreover, the present study is the first to evaluate liver variables in patients undergoing TAVR.
Keywords
LVEFGLDHTAVRAVAChild-Turcotte-PughMCVMPVMCHCCTPNYHAINRMCHALBGGTSTSALTeuroSCOREγ-glutamyl transpeptidaseASTAspartate aminotransferaseAlanine aminotransferaseAlbuminAlkaline phosphataseAVRNew York Heart AssociationChronic obstructive pulmonary diseaseCOPDTranscatheter aortic valve replacementAortic valve replacementThe Society of Thoracic SurgeonsMean corpuscular volumeEuropean System for Cardiac Operative Risk Evaluationbody mass indexBMIlactate dehydrogenaseLDHmean platelet volumemean corpuscular hemoglobinModel for End-Stage Liver Diseaseaortic valve areaMean corpuscular hemoglobin concentrationInternational Normalized Ratioleft ventricular ejection fractionCHECholinesteraseMELDglutamate dehydrogenase
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Daniel MD, Philipp MD, Ali MD, Stephan MD, Martin MD, Gordina Cremer, Fadi MD, Rolf-Alexander MD, Karim MD, Markus MD, Mohamed MD, Philipp MD, Daniel Sebastian MD, Konstantinos MD, Jaroslav MD, Guido MD, Tienush MD, Heinz MD, Matthias MD,